Figure 3.

Effect of lubiprostone on intestinal mucin release. (A) Luminal Lubiprostone. Lubiprostone (1 μM final) was added to the perfusate (luminal) solution after a 30 min equilibration period. The areas under the curves for 20–30 min data (Equilibration) and 30–60 min data (1 μM Lubiprostone) were measured and divided by the time period to determine the rates of mucin release. (n = 2 intestinal segments) (B) Serosal PGE₂, Lubiprostone. Vehicle (Control), PGE₂ (1 μM final), or lubiprostone (Lubi, 1 μM final) was added to the bath (serosal) solution after a 30 min equilibration period. The areas under the curves for 20–30 min data (Equilibration; n = 26 intestinal segments) and 30–60 min data (Control unstimulated, n = 10; PGE₂, n = 9; lubiprostone, n = 7) were measured and divided by the time period to determine the rates of mucin release. (*) p<0.05 vs Control